🏷️ Über: FibroScan® is the non-invasive solution for comprehensive management of liver health. Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.
- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy.
Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.
Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia).
High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
